Pentazocine Hydrochloride and Acetaminophen

×

Overview

What is Pentazocine Hydrochloride and Acetaminophen?

Pentazocine Hydrochloride and Acetaminophen Tablets are a combination of pentazocine hydrochloride, USP, equivalent to 25 mg base and acetaminophen, USP, 650 mg.

Pentazocine is a member of the benzazocine series (also known as the benzomorphan series). Chemically, pentazocine is (2R*,6R*,11R*)1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol, a white, crystalline substance soluble in acidic aqueous solutions, and has the following structural formula:

CHNO HCl M.W. 321.88

Chemically, acetaminophen is Acetamide, -(4-hydroxyphenyl)-, and has the following structural formula:

CHNO M.W. 151.16

Pentazocine is an analgesic and acetaminophen is an analgesic and antipyretic.

Inactive ingredients: colloidal silicon dioxide, FD&C Blue # 1 aluminum lake, microcrystalline cellulose, sodium lauryl sulfate, sodium starch glycolate, and stearic acid.

What does Pentazocine Hydrochloride and Acetaminophen look like?

What are the available doses of Pentazocine Hydrochloride and Acetaminophen?

Sorry No records found.

What should I talk to my health care provider before I take Pentazocine Hydrochloride and Acetaminophen?

Sorry No records found

How should I use Pentazocine Hydrochloride and Acetaminophen?

Pentazocine Hydrochloride and Acetaminophen Tablets are indicated for the relief of mild to moderate pain.

Adult

The usual adult dose is 1 caplet every 4 hours as needed for pain relief, up to a maximum of 6 caplets per day.

Discontinuation

Due to the potential for withdrawal symptoms associated with abrupt discontinuation, consideration should be given to tapering patients off pentazocine hydrochloride and acetaminophen tablets after prolonged periods of treatment with pentazocine hydrochloride and acetaminophen tablets (See , ).

What interacts with Pentazocine Hydrochloride and Acetaminophen?

Sorry No Records found

What are the warnings of Pentazocine Hydrochloride and Acetaminophen?

Sorry No Records found

What are the precautions of Pentazocine Hydrochloride and Acetaminophen?

Sorry No Records found

What are the side effects of Pentazocine Hydrochloride and Acetaminophen?

Sorry No records found

What should I look out for while using Pentazocine Hydrochloride and Acetaminophen?

Pentazocine hydrochloride and acetaminophen tablets are contraindicated in patients who are hypersensitive to either pentazocine or acetaminophen.

Hepatotoxicity

Pentazocine hydrochloride and acetaminophen tablets contain acetaminophen and pentazocine hydrochloride. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products.

The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.

Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.

Hypersensitivity/anaphylaxis

There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergent medical attention. Instruct patients to discontinue pentazocine hydrochloride and acetaminophen tablets immediately and seek medical care if they experience these symptoms. Do not prescribe pentazocine hydrochloride and acetaminophen tablets for patients with acetaminophen allergy.

Drug Dependence

Pentazocine can cause a physical and psychological dependence. (See .)

Use In Head Injury and Increased Intracranial Pressure

In the presence of head injury, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of pentazocine and its potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO2 retention) may be markedly increased. Furthermore, pentazocine can produce effects on pupillary response and consciousness, which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries. In such patients, pentazocine hydrochloride and acetaminophen tablets must be used with extreme caution and only if its use is deemed essential.

Interactions with Alcohol and Drugs of Abuse

Pentazocine may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression because respiratory depression, hypotension, profound sedation, coma or death may result.

Patients Receiving Narcotics

Pentazocine is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the daily treatment of narcotic dependence, have experienced withdrawal symptoms after receiving pentazocine.

Respiratory Depression

Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Use pentazocine hydrochloride and acetaminophen tablets with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or pre-existing respiratory depression. Alternative non-opioid analgesics should be considered, and pentazocine hydrochloride and acetaminophen tablets should be employed only under careful medical supervision at the lowest effective dose in such patients.

Acute CNS Manifestations

Patients receiving therapeutic doses of pentazocine hydrochloride and acetaminophen tablets have experienced hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.

What might happen if I take too much Pentazocine Hydrochloride and Acetaminophen?

How should I store and handle Pentazocine Hydrochloride and Acetaminophen?

Store at 20° to 25° C (68° to 77° F) [See USP Controlled Room Temperature].Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011Pentazocine Hydrochloride and Acetaminophen Tablets are light blue capsule shaped, tablets debossed “NL” on left side and “670” on right side of bisect and plain on the other side.Bottles of 100 (NDC 43386-670-01).Bottles of 100 (NDC 43386-670-05)Store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F). [See USP.]Dispense in a tight, light-resistant container as defined in the USP.DEA Order Form Required. Manufactured by:Novel Laboratories, Inc.Somerset, NJ 08873Distributed by:GAVIS Pharmaceuticals, LLCSomerset, NJ 08873GIN-670-02Rev: 06/2011

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Pentazocine is a Schedule IV opioid analgesic with agonist/antagonist action which when administered orally is approximately equivalent on a mg for mg basis in analgesic effect to codeine.

Acetaminophen is an analgesic and antipyretic.

Pentazocine weakly antagonizes the analgesic effects of morphine, meperidine, and phenazocine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.

Onset of significant analgesia with pentazocine usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer.

Pentazocine is well absorbed from the gastrointestinal tract. Plasma levels closely correspond to the onset, duration, and intensity of analgesia. The time to mean peak concentration in 24 normal volunteers was 1.7 hours (range 0.5 to 4 hours) after oral administration and the mean plasma elimination half-life was 3.6 hours (range 1.5 to 10 hours).

The action of pentazocine is terminated for the most part by biotransformation in the liver with some free pentazocine excreted in the urine. The products of the oxidation of the terminal methyl groups and glucuronide conjugates are excreted by the kidney. Elimination of approximately 60% of the total dose occurs within 24 hours. Pentazocine passes into fetal circulation.

Onset of significant analgesic and antipyretic activity of acetaminophen when administered orally occurs within 30 minutes and is maximal at approximately 2 1/2 hours. The pharmacological mode of action of acetaminophen is unknown at this time.

Acetaminophen is rapidly and almost completely absorbed from the gastrointestinal tract. In 24 normal volunteers the time to mean peak plasma concentration was 1 hour (range 0.25 to 3 hours) after oral administration and the mean plasma elimination half-life was 2.8 hours (range 2 to 4 hours).

The effect of pentazocine on acetaminophen plasma protein binding or vice versa has not been established. For acetaminophen there is little or no plasma protein binding at normal therapeutic doses. When toxic doses of acetaminophen are ingested and drug plasma levels exceed 90 mcg/mL, plasma binding may vary from 8% to 43%.

Acetaminophen is conjugated in the liver with glucuronic acid and to a lesser extent with sulfuric acid. Approximately 80% of acetaminophen is excreted in the urine after conjugation and about 3% is excreted unchanged. The drug is also conjugated to a lesser extent with cysteine and additionally metabolized by hydroxylation.

If pentazocine hydrochloride and acetaminophen tablets are taken every 4 hours over an extended period of time, accumulation of pentazocine and to a lesser extent, acetaminophen, may occur.

Non-Clinical Toxicology

Pentazocine hydrochloride and acetaminophen tablets are contraindicated in patients who are hypersensitive to either pentazocine or acetaminophen.

Hepatotoxicity

Pentazocine hydrochloride and acetaminophen tablets contain acetaminophen and pentazocine hydrochloride. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products.

The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.

Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.

Hypersensitivity/anaphylaxis

There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergent medical attention. Instruct patients to discontinue pentazocine hydrochloride and acetaminophen tablets immediately and seek medical care if they experience these symptoms. Do not prescribe pentazocine hydrochloride and acetaminophen tablets for patients with acetaminophen allergy.

Drug Dependence

Pentazocine can cause a physical and psychological dependence. (See .)

Use In Head Injury and Increased Intracranial Pressure

In the presence of head injury, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of pentazocine and its potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO2 retention) may be markedly increased. Furthermore, pentazocine can produce effects on pupillary response and consciousness, which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries. In such patients, pentazocine hydrochloride and acetaminophen tablets must be used with extreme caution and only if its use is deemed essential.

Interactions with Alcohol and Drugs of Abuse

Pentazocine may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression because respiratory depression, hypotension, profound sedation, coma or death may result.

Patients Receiving Narcotics

Pentazocine is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the daily treatment of narcotic dependence, have experienced withdrawal symptoms after receiving pentazocine.

Respiratory Depression

Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Use pentazocine hydrochloride and acetaminophen tablets with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or pre-existing respiratory depression. Alternative non-opioid analgesics should be considered, and pentazocine hydrochloride and acetaminophen tablets should be employed only under careful medical supervision at the lowest effective dose in such patients.

Acute CNS Manifestations

Patients receiving therapeutic doses of pentazocine hydrochloride and acetaminophen tablets have experienced hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.

Although timolol maleate ophthalmic solution used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with timolol maleate ophthalmic solution and epinephrine has been reported occasionally.

Beta-adrenergic blocking agents:

Calcium antagonists:

Catecholamine-depleting drugs:

Digitalis and calcium antagonists:

CYP2D6 inhibitors:

Clonidine:

Injectable epinephrine:

Pentazocine hydrochloride and acetaminophen tablets are a Schedule IV controlled substance.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of a drug for non-medical purposes, often in combination with other psychoactive substances. Addiction is a disease of repeated drug abuse. Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. Addiction is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time. Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse of the drug for non-medical purposes, and often in combination with other psychoactive substances.

There have been some reports of dependence and of withdrawal symptoms with pentazocine hydrochloride and acetaminophen tablets. Patients with a history of drug dependence should be under close supervision while receiving pentazocine orally. There have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.

There have been reports of development of addiction and physical dependence in patients receiving parenteral pentazocine. People with a history of drug abuse or alcohol abuse may have a higher chance of becoming addicted to opioid medicines.

Abrupt dose cessation or rapid dose reduction following the extended use of parenteral pentazocine has resulted in withdrawal symptoms such as abdominal cramps, nausea, vomiting, elevated temperature, chills, rhinorrhea, restlessness, anxiety, or lacrimation. In general opioid therapy should not be abruptly discontinued. When the patient no longer requires treatment with pentazocine hydrochloride and acetaminophen tablets, the drug should be tapered gradually to prevent signs and symptoms of withdrawal in patients who have been receiving opioids for an extended period of time and might have become physically dependent.

In prescribing pentazocine hydrochloride and acetaminophen tablets for chronic use, the physician should take under consideration that proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to identify and decrease misuse and abuse of opioid drugs.

Severe, even lethal, consequences may result from misuse of tablets by injection either alone or in combination with other substances, such as pulmonary emboli, vascular occlusion, ulceration and abscesses, and withdrawal symptoms in narcotic dependent individuals.

CNS Effect

Caution should be used when pentazocine hydrochloride and acetaminophen tablets are administered to patients prone to seizures; seizures have occurred in a few such patients in association with the use of pentazocine although no cause and effect relationship has been established.

Porphyria

Particular caution should be exercised in administering pentazocine to patients with porphyria since it may provoke an acute attack in susceptible individuals.

Cardiovascular Disease

Pentazocine can elevate blood pressure, possibly through the release of endogenous catecholamines. Particular caution should be exercised in conditions where alterations in vascular resistance and blood pressure might be particularly undesirable, such as in the acute phase of myocardial infarction.

Pentazocine hydrochloride and acetaminophen tablets should be used with caution in patients with myocardial infarction who have nausea or vomiting.

Impaired Renal or Hepatic Function

Decreased metabolism of the drug by the liver in extensive liver disease may predispose to accentuation of side effects. Although laboratory tests have not indicated that pentazocine causes or increases renal or hepatic impairment, the drug should be administered with caution to patients with such impairment.

Acetaminophen is metabolized by the liver, and has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Therefore, pentazocine hydrochloride and acetaminophen tablets should be administered with caution to patients with hepatic impairment and in individuals who ingest alcohol (See and , ).

Other

Caution should also be observed when administering pentazocine hydrochloride and acetaminophen tablets in patients with hypothyroidism, adrenocortical insufficiency, prostate hypertrophy, inflammatory or obstructive bowel disease, acute abdominal syndromes of unknown etiology, cholecystitis, pancreatitis, or acute alcohol intoxication and delirium tremens.

Biliary Surgery

Narcotic drug products are generally considered to elevate biliary tract pressure for varying periods following their administration. Some evidence suggests that pentazocine may differ from other marketed narcotics in this respect (i.e., it causes little or no elevation in biliary tract pressures). The clinical significance of these findings, however, is not yet known.

Clinical experience with pentazocine hydrochloride and acetaminophen tablets have been insufficient to define all possible adverse reactions with this combination. However, reactions reported after oral administration of pentazocine hydrochloride in 50 mg dosage include the following:

Cardiovascular:

Respiratory:

Acute CNS Manifestations:

Other CNS effects:

Autonomic:

Gastrointestinal:

Allergic:

Ophthalmic:

Hematologic:

Dependence and Withdrawal Symptoms:

Other: urinary retention, paresthesia, serious skin reactions, including erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, and alterations in rate or strength of uterine contractions during labor.

A few cases of hypersensitivity to acetaminophen have been reported, as manifested by anaphylaxis, angioneurotic edema, thrombocytopenic purpura, skin rashes, and rarely hemolytic anemia and agranulocytosis. Occasionally individuals respond to ordinary doses with nausea and vomiting and diarrhea.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: